According to our network pharmacology research and GO and KEGG pathway enrichment analyses, it was found that hormone metabolism may play a key role in the treatment of EMs by SZC, and the relevant predicted targets were verified by RT−PCR, revealing that SZC can treat EMs by upregulating ESR1 mRNA expression and inhibiting AR and CYP19A1 mRNA expression in EESCs. This evidence concerns the gene CYP19A1 and eosinophilia-myalgia syndrome.